DolPHIN2 |

Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.

image source: pexels

The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy

The team at the Infectious Diseases Institute, Kampala

DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.

How we work

About DolPHIN 2

Read about the challenges that the DolPHIN 2 project seeks to address and why.

The DolPHIN 2 Consortium

Learn more about our multinational research consortium, comprising partners in Europe and sub-Saharan Africa.

Community Voices

Collaboration with the community is at the heart of DolPHIN 2. Click here to learn more about our community engagement, and to hear from some of our study participants.

Resources

10 Mar 2021

DolPHIN2 Infographic

The DolPHIN 2 Clinical Trial is designed to yield high-quality evidence on the efficacy and safety of dolutegravir in late presenting pregnant women, to allow definitive recommendations for use of dolutegravir to reduce MTCT in this high-risk scenario.

Video

03 Dec 2019

HIV on Trial

Meet our research team, hear from some of our research participants and learn more about the DolPHIN story so far.

Video

28 Nov 2019

They become strong when they see me doing this

Jackie Kyeyune, a peer mother living with HIV, discusses how she uses her lived experience to support and inspire the DolPHIN 2 trial participants.

Video

28 Nov 2019

Trial Management at the Ugandan site

Dr Kenneth Kintu, trial manager at the IDI site, discusses the challenges and rewards of the study, and his hopes for the future

Video

View all Resources

News

The Ugandan Team Celebrates World Breastfeeding Week

08 Aug 2019

DolPHIN-2 presents primary outcome analysis at CROI 2019

05 Mar 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

WHO released a statement on 18 May 2018 relating to a potential safety issue affecting women living with HIV using dolutegravir at the time of conception.

20 Jun 2018

View all News and Events

@UoLDolPHIN2 on Twitter

Celebrating #InternationalDayoftheMidwife and the midwives who delivered the DolPHIN2 infants Watch Sanyu's Story about Giving Birth on https://t.co/baFO7Zvjzr

2 days 11 hours ago

RT @CatrionaWaitt: European HIV Clinical Forum 2021: a mix of plenaries from the experts, interactive Q&A and debate. Aimed at optimising HIV management in Europe, will also be of interest to global colleagues and registration is FREE FOR HEALTHCARE WORKERS. Don't miss out! https://t.co/UXKnPJLPNc https://t.co/AASvbTAREG

2 days 11 hours ago

Co-investigator @CatrionaWaitt will be speaking at the @Academic_MedEdu #HIV clinical forum register at https://t.co/jfv9FCcDR0 https://t.co/LpkM6WNGin

2 days 11 hours ago

We are recruiting Job vacancy at University of Liverpool for an experienced trial manager https://t.co/9eNY8Il1jj @LivUniISMIB @LSTMnews #clinicaltrials #vacancy

4 weeks 1 day ago

DolPHIN2 presented results at #CROI2021 yesterday. This short video explains about DolPHIN2 and some of the results @IDIMakerere @uctcider @radboudumc @LSTMnews @LivUniISMIB @UNITAID #pregnancy #clinicalresearch #ARV #HIV https://t.co/ImWwQgdwSf

1 month 3 weeks ago

#CROI2021 DolPHIN-2 results support @WHO treatment recommendations for use of #DTG in #pregnancy @uctcider @IDIMakerere @radboudumc @LSTMnews @LivUniISMIB @UNITAID https://t.co/uTlvpWgttj

1 month 4 weeks ago

RT @profchloeorkin: #CROI2021 Lockman argues for conceptual shifts to achieve inclusion of pregnant women in research: •Pregnant women are COMPLEX not VULNERABLE •Protect women THROUGH not FROM research •inclusion as default. Great to see our @TheLancetHIV editorial cited as ‘call to arms’ https://t.co/amLgSFjdXZ

1 month 4 weeks ago

RT @drlaurajwaters: #CROI2021 pregnant women with HIV are not niche! Protect them THROUGH research! The DTG-NTD story yielded many lessons & that millions of women received NVP instead of EFV for years based on animal studies & a few case reports also says A LOT! Amazing talk from Shahin Lockman. https://t.co/CFFwTu6K3Y

1 month 4 weeks ago

#CROI2021 Maternal and Child HIV and SARS-CoV-2 session due to start shortly.

1 month 4 weeks ago

Look out for the DolPHIN-2 oral presentation at #CROI2021 tomorrow during the Maternal and Child HIV and SARS-CoV-2 session @uctcider @IDIMakerere @radboudumc @LSTMnews @LivUniISMIB

1 month 4 weeks ago

Congratulations to DolPHIN2 investigator @CatrionaWaitt #breastfeeding #pregnancy https://t.co/5GVr9u0fgQ

4 months 2 weeks ago

DolPHIN2 chief investigator Saye Khoo is a guest on Scouse Science tomorrow. See below to book a free ticket for th… https://t.co/0UBvlHshbU

6 months 3 weeks ago

The D2 Consortium

The DolPHIN 2 consortium is a multinational partnership comprising five research organisations and our funder, Unitaid.

DolPHIN2

Search

How we work

About DolPHIN 2

The DolPHIN 2 Consortium

Community Voices

Resources

DolPHIN2 Infographic

HIV on Trial

They become strong when they see me doing this

Trial Management at the Ugandan site

News

The Ugandan Team Celebrates World Breastfeeding Week

DolPHIN-2 presents primary outcome analysis at CROI 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

@UoLDolPHIN2 on Twitter

The D2 Consortium

University of Liverpool

Liverpool School of Tropical Medicine

Infectious Diseases Institute

University of Cape Town

Radboud University Medical Centre

Unitaid

Contact us

Follow us